ANGLE (OTCPK:ANPC.Y) - Stock Price, News & Analysis

ANPC.Y Stock Overview

ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products in Europe, North America, and the United Kingdom.

About the company

ANPC.Y fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Revenue is forecast to grow 46.64% per year

Risk Analysis

Shares are highly illiquid

Currently unprofitable and not forecast to become profitable over the next 3 years

Does not have a meaningful market cap ($46M)

Does not have meaningful revenue (£2M)

ANGLE plc Competitors

Sensus Healthcare

NasdaqCM:SRTS

US$59.8m

ReWalk Robotics

NasdaqCM:LFWD

US$41.4m

DIH Holding US

NasdaqGM:DHAI

US$63.3m

Asensus Surgical

NYSEAM:ASXC

US$65.5m

Price History & Performance

Summary of all time highs, changes and price drops for ANGLE
Historical stock prices
Current Share Price	UK£1.89
52 Week High	UK£4.00
52 Week Low	UK£1.13
Beta	0.12
1 Month Change	5.00%
3 Month Change	1.61%
1 Year Change	-48.08%
3 Year Change	-88.19%
5 Year Change	-77.45%
Change since IPO	-85.87%

Recent updates

Shareholder Returns

	ANPC.Y	US Medical Equipment	US Market
7D	0%	0.007%	0.7%
1Y	-48.1%	-1.0%	23.9%

Return vs Industry: ANPC.Y underperformed the US Medical Equipment industry which returned -1% over the past year.

Return vs Market: ANPC.Y underperformed the US Market which returned 23.9% over the past year.

Price Volatility

Is ANPC.Y's price volatile compared to industry and market?
ANPC.Y volatility
ANPC.Y Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	7.5%
Market Average Movement	6.1%
10% most volatile stocks in US Market	16.7%
10% least volatile stocks in US Market	3.0%

Stable Share Price: ANPC.Y's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine ANPC.Y's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1994	173	Andrew David Newland	angleplc.com

ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products in Europe, North America, and the United Kingdom. The company develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in metastatic breast cancer patient blood; and HyCEAD. ANGLE plc has a partnership agreement with Bio View Ltd to develop a liquid biopsy circulating tumor cell HER2 assay for breast cancer.

ANGLE plc Fundamentals Summary

How do ANGLE's earnings and revenue compare to its market cap?
ANPC.Y fundamental statistics
Market cap	US$58.02m
Earnings (TTM)	-US$27.96m
Revenue (TTM)	US$2.28m

25.4x

P/S Ratio

-2.1x

P/E Ratio

Is ANPC.Y overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ANPC.Y income statement (TTM)
Revenue	UK£1.82m
Cost of Revenue	UK£1.50m
Gross Profit	UK£319.00k
Other Expenses	UK£22.60m
Earnings	-UK£22.28m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-0.086
Gross Margin	17.55%
Net Profit Margin	-1,225.41%
Debt/Equity Ratio	0%

How did ANPC.Y perform over the long term?

See historical performance and comparison

ANPC.Y Stock Overview

Rewards

Risk Analysis

ANGLE plc Competitors

NasdaqCM:SRTS

US$59.8m

NasdaqCM:LFWD

US$41.4m

NasdaqGM:DHAI

US$63.3m

NYSEAM:ASXC

US$65.5m

Price History & Performance

Recent News & Updates

ANGLE plc, Annual General Meeting, Jun 26, 2024

Angle plc Announces Use of Parsortix System in Pre-Clinical Model Unlocks Opportunities for Drug Discovery

ANGLE plc Launches Portrait+ CTC Kit At SABCS

ANGLE plc Provides Earnings Guidance for the Year 2023

ANGLE plc Provides Earnings Guidance for the Year 2023

ANGLE plc Announces the Launch of Its Portrait® PD-L1 Test for the Evaluation of PD-L1 Protein Expression on CTCs Following Extensive Development and Optimisation

Recent updates

ANGLE plc, Annual General Meeting, Jun 26, 2024

Angle plc Announces Use of Parsortix System in Pre-Clinical Model Unlocks Opportunities for Drug Discovery

ANGLE plc Launches Portrait+ CTC Kit At SABCS

ANGLE plc Provides Earnings Guidance for the Year 2023

ANGLE plc Provides Earnings Guidance for the Year 2023

ANGLE plc Announces the Launch of Its Portrait® PD-L1 Test for the Evaluation of PD-L1 Protein Expression on CTCs Following Extensive Development and Optimisation

Angle plc Announces the Launch of Its Portrait™ Flex Ctc Assay

ANGLE plc Announces Senior Management Appointments

ANGLE plc Announces Board Changes

ANGLE plc Announces Appointment of Joseph (Joe) Eid as Non-Executive Director

ANGLE plc to Report Fiscal Year 2022 Results on Jun 02, 2023

ANGLE plc Announces Appointment of Juliet Thompson as Non-Executive Director

ANGLE plc Announces the Publication of Results from A Multi-Centre Clinical Study

Angle plc Announces It Presented Results from A Proof of Concept Study At the International Society of Liquid Biopsy Meeting in Miami, Florida

ANGLE plc Announces Streamlining of Operations to Increase Cash Runway

ANGLE plc Announces Positive Headline Results from Ovarian Study

ANGLE plc Announces Study Using Parsortix in Head and Neck Cancer

ANGLE plc Announces the Publication of Results from A Clinical Study Undertaken in Partnership with the Wilmot Cancer Institute, University of Rochester, NY, US

Angle plc Announces New Study Highlights Use of Parsortix System to Enable Cancer Cell Dna Analysis in Non-Small Cell Lung Cancer

ANGLE plc Announces Ground-Breaking Research by the World-Class Team at the Molecular Oncology Laboratory at the Swiss Federal Institute of Technology Zurich, Switzerland

Angle plc Announces Results of Work Undertaken in Advanced Non-Small Cell Lung Cancer (NSCLC) and Sarcoma Patients

Angle plc Receives FDA Clearance for Parsortix

ANGLE plc, Annual General Meeting, Jun 29, 2022

ANGLE plc to Report Fiscal Year 2021 Results on Apr 28, 2022

Angle Announces Parsortix System Shows Potential for Providing Rapid Information on Patient Response to Therapies Targeting Metastasis

ANGLE plc Announces the Edith Cowan University, Perth, Australia, Has Published Results from A Study in Ovarian Cancer Patients Using the Parsortix® System

ANGLE plc Announces the Publication of Research Undertaken by the World-Class Team At the University of Southern California Norris Cancer Center

ANGLE plc Provides Update on Lab Accreditation and Ovarian Study

ANGLE plc Announces Parsortix System Demonstrates Ability to Isolate CTCS for Downstream Gene Analysis Revealing Multiple Prognostic Biomarkers

Angle plc Announces That the Health Research Institute of Santiago

ANGLE plc Announces Published Results of A New Study Undertaken in Non-Small Cell Lung Cancer

Angle plc Announces Breakthrough Research Supports Potential Use of Parsortix in Prevention of Relapse of Breast Cancer Patients in Remission

Angle's Parsortix System Harvests Intact CTCs for Whole Genomic Sequencing Identifying Multiple Druggable Targets

ANGLE plc Announces Patient Enrolment Completed in Ovarian Cancer Clinical Verification Study

Angle plc Provides Update on Submission for FDA Clearance of the Parsortix System

Angle plc Announces Results of New Study Undertaken in Non-Small Cell Lung Cancer

ANGLE plc Announces Publication of New Data Demonstrating the Performance of its Parsortix® System in a Head-to-Head Comparison with a Antibody-Based CTC System

ANGLE plc Announces FDA Completes its Administrative Review and Accepts ANGLE's FDA Submission for Substantive Review

ANGLE plc Announces Completion of FDA Submission

ANGLE plc Announces Potential Treatment Strategy to Limit Metastasis

ANGLE plc to Report 8 Months Period Ending Dec 31, 2019 Results on Jun 25, 2020

ANGLE plc to Report First Half, 2020 Results on Oct 29, 2020

Shareholder Returns

Price Volatility

About the Company

ANGLE plc Fundamentals Summary

25.4x

-2.1x

Earnings & Revenue